In human essential hypertension (EH), endothelium-dependent relaxation can occur independent of nitric oxide (NO) and prostacyclin (PGI 2 ). Recent in vivo data suggest that rapid compensatory upregulation of endothelial cytochrome P450 epoxygenase 2C9 occurs to preserve vasorelaxation under conditions of decreased NO bioavailability. As one of the vascular actions of CYP2C9 is to modulate small and intermediate conductance endothelial calcium-activated potassium channels (SK Ca and IK Ca ), we examined whether endothelium-dependent relaxation is sensitive to inhibitors of these channels (apamin and charybdotoxin) in resistance-sized vessels from human with EH. Subcutaneous gluteal biopsies were performed on 12 humans with EH and 12 matched control subjects. Resistance arteries were dissected and relaxation responses to carbachol were assessed ex vivo using wire myography in the presence of: (i) N G -nitro-L-arginine (L-NOARG)/indomethacin; and (ii) apamin/charybdotoxin.
Introduction
Human essential hypertension (EH) is characterized by decreased nitric oxide (NO) bioavailability. 1 Many, [2] [3] [4] but not all, 5, 6 studies have reported impaired small vessel relaxation to agonists stimulating endothelial G-protein-coupled receptors including acetylcholine (ACh), carbachol and bradykinin. Recent data from in vivo human forearm plethysmography studies indicate that ACh relaxation in EH is resistant to inhibitors of endothelial nitric oxide synthase (eNOS), 7 and that pathways independent of NO and prostacyclin (PGI 2 ) mediate arterial relaxation under such conditions. 8 A recently published study by Taddei et al. 9 has reported that ACh responses in the forearm of subjects with EH are sensitive to intra-brachial infusions of sulphaphenazole, an inhibitor of cytochrome P450 epoxygenase (CYP2C9). 9 On the basis of these data, these investigators suggest that a CYP2C9 product (11, 12 epoxyeicosatrienoic acid (11, 12 EET)) plays a key role in human EH as an endothelium-derived hyperpolarizing factor (EDHF) producing rapid compensatory vasorelaxation under conditions of decreased NO bioavailability. 9 The EDHF is a complex and multifaceted response, [10] [11] [12] [13] [14] [15] [16] playing a particularly prominent role in smaller resistance-sized vessels. 17 Evidence from eNOS-and cyclo-oxygenase-deficient mice is generally, 18, 19 although not universally, 14 consistent with this proposed compensatory role for EDHFmediated arterial relaxation under conditions of NO deficiency. In human vessels, activation of endothelial calcium-dependent potassium channels, particularly those of small (SK Ca ) and intermediate (IK Ca ) conductance, is known to play a key role in endothelial cell hyperpolarisation, which is central to many EDHF-mediated responses. 20 There is considerable evidence that 11,12 EET acts within endothelial cells to increase or 'amplify' the sensitivity of these channels to calcium, although it can also produce relaxation per se by crossing the myoendothelial space to act on smooth muscle cell large conductance calcium-activated potassium channels (BK Ca ). 21 In the present study, we have examined whether endothelium-dependent relaxation in small resistance-sized arteries from patients with EH is sensitive to combined inhibition of SK Ca (apamin), IK Ca and BK Ca (charybdotoxin).
Materials and methods
Twelve male patients aged 30-65 years with EH (mean systolic BP4160 mm Hg or diastolic BP490 mm Hg measured in triplicate using a standardized technique on at least three separate occasions) 22 were recruited from the Hypertension Clinic at Glasgow Royal Infirmary. Patients with diabetes, with a history of previous cardiovascular events, or who were taking statins were not recruited. Where applicable, prescribed anti-hypertensive medication was stopped 14 days before study assessment. Twelve healthy control subjects were also recruited from a panel of healthy volunteers. A single investigator (CS) performed all assessments. The protocol was approved by the North Glasgow Hospitals University NHS Trust ethical review committee; all subjects gave fully informed written consent and the investigation conformed to the principles of the Declaration of Helsinki. 23 
Gluteal biopsy
Participants attended fasting having abstained from smoking for at least 12 h. Subcutaneous gluteal fat (3-5 g) was obtained from each participant under local anaesthesia (lidocaine 1%) according to standard methods. 24 Tissue was placed immediately into cold 0.9% NaCl before being transferred to PSS solution (NaCl 118. 4 Myography protocol Artery preparation. At least two arteries approximately 2 mm in length and less than 300 mm in diameter were dissected free of fat from each EH and control biopsies and were mounted on two 40 mm diameter stainless-steel wires on a four-channel Mulvany-Halpern wire myograph (Danish Myotech, Denmark). Temperature was raised to 371C, and a gas mixture (as above) was perfused for the duration of the experiment.
Normalization. After mounting, vessels underwent a normalization protocol. 25 Briefly, after a rest period of 45 min, each artery was stretched at 1-min intervals to determine the passive exponential wall tension-internal circumference (L) relationship. From the Laplace equation, where P ¼ T/r (where P is the effective pressure, T is the wall tension and r is the internal radius), the equivalent circumference (L 100 ) for a transmural pressure of 100 mm Hg was calculated for each vessel by an iterative method. Each vessel was then set to the normalized internal diameter, L 1 ¼ 0.9L 100 /p, at which contraction is thought to be optimal. 26 One hour later, vessels were exposed to a high concentration (123 mM) of potassium (KPSS, sodium replaced by potassium on an equimolar basis) for a series of 5-min periods until repeatable maximal contractions were achieved. Endothelial integrity was then tested in each vessel by ensuring vasorelaxation to carbachol (10 À5 M), following preconstriction with norepinephrine (3 Â 10 À7 M).
Pharmacological assessment. In both channels, the first experiment consisted of preconstriction with 3 Â 10 À7 M norepinephrine (NE) followed by cumulative addition of carbachol (10 À9 to 10 À5 M), then a washout with PSS. Thereafter, the vessel in Channel 1 underwent a 30 min preincubation with N G -nitro-L-arginine (L-NOARG) (10 À4 M) and indomethacin (10 À5 M) [combined inhibition of NO synthase/cyclooxygenase], while the vessel in Channel 2 underwent a simultaneous 30 min preincubation with apamin (10 À7 M) and charybdotoxin (10 À7 M) to inhibit SK Ca , IK Ca , BK Ca . Vessels in both channels subsequently underwent repeated preconstriction with 3 Â 10 À7 M norepinephrine followed by cumulative addition of carbachol (10 À9 to 10 À5 M) and a washout with PSS. Finally, cumulative response to the endothelium-independent vasodilator agonist S-nitroso-N-acetyl-penicillamine (SNAP) was assessed in vessels in both channels by adding increasing concentrations (10 À9 -10
Statistical analysis
Results are expressed as mean7s.e.m. Relaxation responses to carbachol are expressed relative to the maximum preconstriction to NE as a percentage. Contractile responses to NE are expressed relative to the maximal contraction to KPSS (as a percentage).
In the case of cumulative concentration-response curves generated with carbachol and SNAP, the pD2 (negative log concentration of agonist required to effect a 50% response) was calculated. As a 50% response (required for pD2 calculation) was not achieved following incubation with either L-NOARG/indomethacin or apamin/charybdotoxin in the concentration range studied, these responses were compared using one-way ANOVA for repeated measures. pD2 and maximum response values were compared using Student's t-test (unpaired).
Results

Subjects
Baseline characteristics of control and hypertensive subjects are given in Table 1 . Of the 12 hypertensive subjects, three had been taking Angiotensin Converting Enzyme Inhibitors and five had been taking b-blockers until two weeks before study; four were treatment-naïve, and none had been taking angiotensin II receptor blockers.
Resistance arteries
The biopsy procedure was well tolerated by all subjects. The mean (s.e.m.) internal diameters of the dissected resistance arteries were 337.8721.1 mm from EH and 312.9712.5 mm from control subjects (P ¼ 0.29). No differences in maximal contractile response to NE or KPSS were detected between the groups (maximal KPSS contraction 3.5770.25 mN/ mm in hypertensive patients vs 3.2670.18 mN/mm in controls).
Endothelium-dependent relaxation Relaxation to carbachol. A significant impairment of maximal relaxation (Po0.05) was observed in hypertensive subjects, although no difference in pD 2 was detected ( Figure 1 ).
Effect of L-NOARG/indomethacin and apamin/ charybdotoxin Control subjects. Attenuated relaxation to carbachol was observed following incubation with L-NOARG/ indomethacin (Po0.01 ANOVA). No significant attenuation was observed following incubation with apamin/charybdotoxin (Figure 2a) . EH subjects. In contrast to observations in vessels from control subjects, attenuated relaxation to carbachol was observed following incubation with apamin and charybdotoxin (Po0.001 ANOVA) (Figure 2b ). There was no significant attenuation in relaxation following incubation with L-NOARG/ indomethacin.
Endothelium-independent relaxation
No differences in relaxation to SNAP (maximal or pD 2 ) were observed between EH and control vessels ( Figure 3 ).
Discussion
Consistent with a number of previous studies, 2-4 we observed a small impairment in maximal arterial relaxation to the endothelium-dependent agonist carbachol in small resistance-sized arteries dissected from human gluteal biopsies from patients with EH. Calcium-activated potassium channel blockade in hypertension CAR Sainsbury et al
More significantly, we report that endotheliumdependent relaxation in these vessels was resistant to combined eNOS and PGI 2 inhibition, but sensitive to blockade of calcium-activated potassium channels. This latter observation is in accordance with the results of previous and recent in vivo forearm studies 7, 9 in that it implicates pathways independent of NO and PGI 2 in mediating arterial relaxation under conditions of impaired NO bioavailability. Our ex vivo findings using inhibitors unsuitable for in vivo administration extend previous knowledge as they implicate a role in this response in EH for activation of calcium-activated potassium channels, 20 which are known to interact with the CYP2C product 11,12 EET in mediating endothelium-dependent hyperpolarization in many vascular beds. 21 Impaired relaxation responses to acetylcholine (ACh) and other endothelium-dependent agonists have previously been reported in some, [2] [3] [4] but not in all 5, 6 investigations of EH. Differences in methods of vascular assessment, size of vessel studied, experimental conditions and patient selection (including disease duration and gender) may account for some of these discrepancies. More recently, it has become clear that at least three independently regulated mechanisms 20, 21 play a role in endothelium-dependent relaxation responses. It should be noted that appropriate inhibitors for formal dissection of the relative contributions of NO, PGI 2 and other pathways were not available at the time of many of the above investigations, and even now those required to assess the role of calcium-activated potassium channels are too toxic for in vivo administration.
Given that we and others 9 have reported an apparently compensatory arterial relaxation under conditions of eNOS and cyclo-oxygenase inhibition, it is tempting to invoke involvement of an EDHF or related mechanism. Demonstration of endothelial SK Ca and IK Ca activation is considered critical to the accepted definition of EDHF. 20 Our use of the inhibitor charybdotoxin, which blocks BK Ca channels on smooth muscle cells in addition to IK Ca and SK Ca , does not exclude the possibility of direct action of 11,12 EET across the myoendothelial space. Although such a mechanism originates in the endothelium and involves hyperpolarization of smooth muscle cells, it is not considered 'EDHFmediated' in that the mediator is known. 20 Further studies are required using more specific inhibitors of IK Ca to clarify this issue, but this does not detract from our observation that endothelium-dependent relaxation was differentially sensitive to inhibition of calcium-activated potassium channels in EH vs control human subjects.
As discussed above, a recent report has implicated the CYP2C9 product 11,12 EET in compensatory arterial relaxation in EH. 9 Given that 11,12 EET is involved in intracellular regulation of SK Ca and IK Ca Calcium-activated potassium channel blockade in hypertension CAR Sainsbury et al sensitivity to calcium, 21 we consider our results consistent with the interpretation that upregulation of pathways considered to be involved in 'EDHFmediated' responses acts to preserve arterial relaxation in this condition. We recognize, however, that the situation is complex and alternative interpretations exist; for example, metabolism of 11,12 EETs by soluble epoxide hydrolase could be altered in EH, or smooth muscle cells could exhibit enhanced 11,12 EET sensitivity. A further complexity is that, as well as synthesizing 11,12 EET, CYP2C9 can also generate superoxide anions, particularly in established coronary artery disease. 27 However, reversal of sulphaphenazole inhibition of endothelium-dependent relaxation in EH during vitamin C coinfusion is not in keeping with a role for CYP2C as a relevant source of oxidative stress in this context. 9 The notion that arterial relaxation can be preserved under condition of chronic decreased NO bioavailability is supported by the above-mentioned studies in resistance arteries of eNOS-deficient mice 18, 19 and is elaborated by studies in mice deficient in both eNOS/and cyclo-oxygenase-1. 28 In the latter model, high blood pressure was evident in males, in which 'non-NO, non-PGI 2 ' responses were much less marked than in females. These observations suggest a causal relationship between small vessel EDHF-mediated responses and blood pressure phenotype, and provide an example of the capacity of one endothelial vasodilator systems to compensate when another is impaired, at least in rodent models and in the longer term. Another relevant example is a reported shift towards EDHF rather than NO dependence of endothelial relaxation responses to bradykinin following balloon damage and repair in porcine coronary arteries (in which 11,12 EETs play an important role). 29 Can EDHF-type compensation occur acutely? Hyperpolarization in cultured rat aortic smooth muscle cells and ACh-mediated relaxation in rabbit carotid arteries can be rapidly inhibited by NO donors under conditions of combined eNOS and cyclo-oxygenase inhibition. 29 The results of the above-mentioned in vivo study by Taddei et al. 9 are also in keeping with acute regulation of CYP2C by NO. However, SK Ca and IK CA responses as examined in the present study have to date been considered independently regulated from CYP2C and unaffected by NO bioavailability. 20 Although our study involved detailed and carefully performed measurements with few missing data in a small number of subjects, it has clear limitations. Hypertensive patients were wellmatched with control subjects for age and fasting glucose, but were more obese (mean BMI 31.0 vs 26.1 kg/m 2 , Table 1 ). Given the relatively small number of subjects studied, it was not possible to perform a valid statistical correction of individual arterial responses; however, vascular results were unaffected (data not shown) when data from the single heaviest hypertensive and lightest control subject were removed, diminishing the BMI difference (adjusted mean BMI 30.3 vs 26.6 kg/m 2 ). Given that we were working with small biopsies donated on a one-off basis by human participants, we used a rather specific range of agonists and inhibitors, resulting in limited insights into detailed mechanisms. We used only one 'endotheliumdependent' agonist (carbachol, a stable analogue of ACh, selected on the basis of our published experience 30, 31) and used combined L-NOARG and indomethacin inhibition, rather than separate inhibition of PGI 2 and NO responses. We did not examine the effect on carbachol relaxation of addition of L-NOARG/indomethacin to pre-existing apamin/charybdotoxin blockade, or vice versa. This approach would have permitted more detailed and quantitative assessment of the relative roles of the individual systems. Although we demonstrated that vascular smooth muscle was similarly sensitive to NO in EH and control subjects using the 'endothelium-dependent' agonist SNAP, we did not examine carbachol relaxation or the effects of inhibitors in endothelium-denuded vessels (which would have allowed us more confidently to attribute the differences we observed to endothelial mechanisms). Finally, we did not include a control experiment in the presence of oxyhaemoglobin (an NO scavenger) to exclude L-NOARG-insensitive release of NO from either photosensitive or adventitial stores.
Despite these limitations, our results, taken in the context of recent data from the literature, permit teleological speculation, which in EH upregulation of pathways independent of NO and PGI 2 , may compensate at least in part for impaired endothelium-dependent relaxation under conditions of reduced NO bioavailability. It remains unclear whether this can occur over a short time course, whether it can be maintained over time, whether it differs between individuals and whether it might contribute to physiological or pathophysiological human blood pressure regulation. As both NO-and EDHF-mediated responses have effects other than on vascular tone (including antiplatelet activity, inhibition of cellular adhesion, regulation of basement membrane composition; regulation of cell proliferation and angiogenesis), the possibility exists that changes in the predominant mechanism of arterial relaxation in association with a pathophysiological state might contribute to changes in cardiovascular prognosis. Whether or not this is the case, there are clear implications of our findings for future clinical studies assessing endothelial function with endothelium-dependent agonists such as ACh and carbachol in the absence of NO/ EDHF inhibitors, particularly in EH.
In summary, we report the novel finding that endothelium-dependent relaxation in human EH is resistant to combined eNOS and PGI 2 inhibition, but sensitive to blockade of calcium-activated potassium channels. This observation is in accordance with recent reports from in vivo forearm circulation studies in patients with EH that pathways independent of NO and PGI 2 can mediate arterial relaxation under conditions of impaired NO bioavailability. If confirmed, our observations, which are also consistent with some available data from transgenic rodent models, may enhance understanding of the complex pathophysiology underlying the development of human EH.
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